Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JENNIFER LYNN NASH

Allopathic & Osteopathic Physicians Dermatology

NPI
1518924299
CMS profile
341673
Location
WESTERVILLE, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$940.34

56 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $940.34 56

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 56 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JENNIFER LYNN NASH

NPI 1518924299 · CMS profile ID 341673

Allopathic & Osteopathic Physicians / Dermatology

WESTERVILLE, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 56 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1518924299?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JENNIFER LYNN NASH, NPI 1518924299, CMS profile ID 341673. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 56 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518924299?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JENNIFER LYNN NASH, NPI 1518924299, CMS profile ID 341673. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 56 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518924299?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JENNIFER LYNN NASH, NPI 1518924299, CMS profile ID 341673, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 56 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1518924299?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

56 matching records · $940.34 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 56 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 56.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $25.8412/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918107717 CMS
Sun Pharmaceutical Industries Inc. $17.1712/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947796169 CMS
ABBVIE INC. $17.8511/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891235667 CMS
MAYNE PHARMA INC. $21.9311/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959932655 CMS
ABBVIE INC. $14.9911/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891235665 CMS
ABBVIE INC. $11.0711/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891235663 CMS
Janssen Biotech, Inc. $17.1411/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886371213 CMS
ABBVIE INC. $1.5810/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891235659 CMS
ABBVIE INC. $20.4210/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891235661 CMS
E.R. Squibb & Sons, L.L.C. $16.8610/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932620685 CMS
Sun Pharmaceutical Industries Inc. $18.3210/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947796165 CMS
Sun Pharmaceutical Industries Inc. $24.2109/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947796177 CMS
ABBVIE INC. $22.1609/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891235657 CMS
ABBVIE INC. $21.1509/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891235655 CMS
ABBVIE INC. $19.5408/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891235653 CMS
Lilly USA, LLC $25.1008/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918093347 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.5608/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887528055 CMS
ABBVIE INC. $22.4408/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891235651 CMS
ABBVIE INC. $1.4208/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891235647 CMS
ABBVIE INC. $11.5408/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891235649 CMS
ABBVIE INC. $16.6307/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891235645 CMS
ABBVIE INC. $13.5407/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891235643 CMS
Regeneron Healthcare Solutions, Inc. $23.0207/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927298271 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.0306/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887528057 CMS
GENZYME CORPORATION $22.8906/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938869423 CMS
Janssen Biotech, Inc. $17.9806/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886371207 CMS
GENZYME CORPORATION $26.0705/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938869419 CMS
ABBVIE INC. $16.3305/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891235641 CMS
Novartis Pharmaceuticals Corporation $13.4905/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894015591 CMS
Incyte Corporation $20.6105/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943074407 CMS
ABBVIE INC. $6.3505/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891235639 CMS
Galderma Laboratories, L.P. $14.1504/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952287755 CMS
Lilly USA, LLC $16.8104/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918090549 CMS
ABBVIE INC. $17.2804/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891235637 CMS
ABBVIE INC. $20.7004/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891235635 CMS
Janssen Biotech, Inc. $18.2104/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886371201 CMS
GENZYME CORPORATION $16.4004/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938869407 CMS
Novartis Pharmaceuticals Corporation $12.6004/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894015587 CMS
ABBVIE INC. $25.7403/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891235633 CMS
Incyte Corporation $18.0203/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943074371 CMS
Janssen Biotech, Inc. $16.5103/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886371195 CMS
Regeneron Healthcare Solutions, Inc. $19.1103/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927298266 CMS
ABBVIE INC. $11.0403/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891235629 CMS
ABBVIE INC. $2.1003/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891235631 CMS
PFIZER INC. $12.6903/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949599831 CMS
Lilly USA, LLC $15.6803/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918157677 CMS
Journey Medical Corporation $11.9502/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924776321 CMS
ABBVIE INC. $13.4502/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891235627 CMS
Lilly USA, LLC $16.6302/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918127735 CMS
Amgen Inc. $15.1502/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939179373 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $805.11 23
PY2020 $469.87 19
PY2021 $826.06 49
PY2022 $940.34 56
PY2023 $1,456.33 76
PY2024 $1,893.47 104
PY2025 $1,665.20 83

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $243,014.48 48
PY2024 Recipient $1,267.72 7
PY2024 Principal investigator $137,527.38 8
PY2023 Principal investigator $787,642.30 65
PY2022 Recipient $187.10 4
PY2022 Principal investigator $974,316.67 62
PY2021 Recipient $890.12 6
PY2021 Principal investigator $503,922.68 30
PY2020 Principal investigator $730,035.42 59
PY2019 Principal investigator $647,335.59 32

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

48 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $10,083.36 12/31/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study No dispute reported 06/30/2026 1202534931
Principal investigator 1 ABBVIE INC. $11,958.15 12/04/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202528484
Principal investigator 1 ABBVIE INC. $399.60 11/11/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202523781
Principal investigator 1 ABBVIE INC. $199.80 11/11/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202523783
Principal investigator 1 ABBVIE INC. $199.80 11/11/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202523785
Principal investigator 1 ABBVIE INC. $599.40 11/11/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202523787
Principal investigator 1 ABBVIE INC. $399.60 11/10/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202523705
Principal investigator 1 ABBVIE INC. $12,000.00 11/05/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202523031
Principal investigator 1 ABBVIE INC. $13,612.65 10/09/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202515945
Principal investigator 1 ABBVIE INC. $20,398.05 09/04/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202508574
Principal investigator 1 ABBVIE INC. $799.20 08/08/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504087
Principal investigator 1 ABBVIE INC. $399.60 08/08/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504089
Principal investigator 1 ABBVIE INC. $799.20 08/08/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504091
Principal investigator 1 ABBVIE INC. $799.20 08/08/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504093
Principal investigator 1 ABBVIE INC. $1,198.80 08/08/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504095
Principal investigator 1 ABBVIE INC. $199.80 08/08/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504111
Principal investigator 1 ABBVIE INC. $999.00 08/08/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504113
Principal investigator 1 ABBVIE INC. $599.40 08/08/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504115
Principal investigator 1 ABBVIE INC. $1,398.60 08/08/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504117
Principal investigator 1 ABBVIE INC. $599.40 08/08/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504119
Principal investigator 1 ABBVIE INC. $399.60 08/08/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504121
Principal investigator 1 ABBVIE INC. $799.20 08/08/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504129
Principal investigator 1 ABBVIE INC. $799.20 08/08/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504131
Principal investigator 1 ABBVIE INC. $999.00 08/08/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504133
Principal investigator 1 ABBVIE INC. $13,612.65 08/06/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202503397
Principal investigator 1 ABBVIE INC. $199.80 07/30/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202500482
Principal investigator 1 ABBVIE INC. $599.40 07/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202500176
Principal investigator 1 ABBVIE INC. $199.80 07/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202500178
Principal investigator 1 ABBVIE INC. $50.00 07/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202500180
Principal investigator 1 ABBVIE INC. $399.60 07/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202500182
Principal investigator 1 ABBVIE INC. $199.80 07/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202500184
Principal investigator 1 ABBVIE INC. $199.80 07/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202500186
Principal investigator 1 ABBVIE INC. $399.60 07/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202500192
Principal investigator 1 ABBVIE INC. $1,198.80 07/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202500194
Principal investigator 1 ABBVIE INC. $399.60 07/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202500196
Principal investigator 1 ABBVIE INC. $199.80 07/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202500198
Principal investigator 1 ABBVIE INC. $168.75 07/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202500202
Principal investigator 1 ABBVIE INC. $326.70 07/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202500234
Principal investigator 1 ABBVIE INC. $500.00 07/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202500236
Principal investigator 1 ABBVIE INC. $199.80 07/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202500238
Principal investigator 1 ABBVIE INC. $1,000.00 07/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202500240
Principal investigator 1 ABBVIE INC. $723.27 07/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202500242
Principal investigator 1 ABBVIE INC. $26,221.50 07/02/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202496215
Principal investigator 1 ABBVIE INC. $17,514.30 06/03/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202489105
Principal investigator 1 ABBVIE INC. $30,106.95 05/07/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202482641
Principal investigator 1 ABBVIE INC. $8,982.60 04/03/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202471898
Principal investigator 1 ABBVIE INC. $31,995.00 03/07/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202461472
Principal investigator 1 ABBVIE INC. $26,977.35 02/06/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202447585